FY17-OCME- NIST Traceable Drug Standards

The District of Columbia's Office of the Chief Medical Examiner (OCME) is seeking a procurement for NIST Traceable Drug Standards, as indicated by the contract opportunity posted on March 21, 2017, with a very tight response deadline of March 23, 2017. This procurement appears to be a specialized scientific acquisition targeting forensic drug testing standards, with specific requirements for laboratory-grade reference materials that are precisely calibrated and traceable to the National Institute of Standards and Technology (NIST). The contract seems focused on obtaining high-precision drug testing standards that can be used for forensic analysis, toxicology research, and potentially legal evidence preparation. The extremely short turnaround time between posting and response deadline suggests this may be an urgent or time-sensitive procurement with potentially expedited evaluation and selection processes. While detailed evaluation criteria are not explicitly provided, the specialized nature of the procurement implies stringent technical qualifications and compliance requirements for potential vendors.

Given the limited information available, it is unclear whether specific set-aside designations or vendor restrictions are in place for this contract opportunity. The procurement does not indicate explicit preferences for disadvantaged business enterprises or small business participation. No incumbent vendors or current contractors are mentioned in the provided documentation. The contract appears to be a focused, specialized scientific procurement without broad competitive solicitation characteristics. Without additional context, the potential award value or budget range cannot be definitively determined. Potential respondents would need to carefully review the full solicitation documentation to understand the precise technical specifications, compliance requirements, and potential financial scope of the NIST Traceable Drug Standards procurement for the District of Columbia's Office of the Chief Medical Examiner.